Validation of AIA-360 for Determination of Presepsin: A Useful Tool for the Diagnosis of Sepsis at the Emergency Department
Sepsis is a systemic syndrome, originally conceptualized as the decomposition of animal or vegetable matter in the presence of bacteria. Currently, sepsis is defined as a life-threatening condition that arises when the body’s response to an infection injures its tissues and organs. Sepsis is one of the main causes of mortality in both emergency departments (ED) and intensive care units (ICU), due to the main difficulty of the early recognition and appropriate identification of the etiology. Therefore, it is imperative to identify a useful biomarker for early diagnosis, with high effectiveness and efficiency, as well as good sensitivity and specificity.
Results demonstrate the great performance of the automated instrument, AIA-360, showing good precision, repeatability, great linearity and no carryover effect. From the results presented, Presepsin appears to be a promising biomarker for the evaluation of sepsis in discerning the control groups from the confirmed sepsis group at the ED and in assisting physicians in the initial evaluation of patients. Furthermore, the presepsin test with the AIA-360 instrument could have some advantages in the management of septic patients admitted to an emergency department, due to the rapid and precise results obtained.
Thus, presepsin could be a useful biomarker in reducing the workload of ED, thus favoring the hospital rule-in or rule-out of patients already at the triage stage.
Link to read and download the complete article:
Link to view product: